RE:RE:K2 acquires some moreProbably. I emailed Scott the other day and he said both companies were operating as distinct entities until shareholders approved the merger. TRX will want to keep chugging in the event the merger falls through. I figure even if the merger falls through for some weird reason, Fibricor and Medical Futures puts us around the $1.50/share mark with Bilastine a couple months out - so I'm not worried no matter what happens. If/when the merger does get approved, we'll have Yosprala/Bilistine/Bezalip in the pipe with the US exchange hedge thrown in there. Keep an eye on that Iran/US deal (oil price) and North American interest rates as they both will affect the price of TRX inasmuch as TRX ownership acts as a hedge against the Canadian dollar which could be sitting at .70US by the fall - it wouldn't suprise me.
I've got an email into POZN with some acquisition questions but haven't heard anything back yet - will pass on any information I get. It wouldn't surprise me if POZN traded in circles until Q4, surprising earnings aside. This stock might bore the heck out of some investors right now but the current risk is quite low with a large upside for Q4 and into 2016. Also, it should be remembered, that if shares of POZN collapse for whatever reason (can't forsee that given the nature of their revenue streams), TRX shareholders can always pull the plug on the deal. Lots of armor here.